Clinical Trials Directory

Trials / Completed

CompletedNCT00809042

Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia

The Effect of Combination Therapy of Hydroxyurea With L- Carnitine and Magnesium Chloride on he-Matologic Parameters and Cardiac Function of β-Thalassemia Intermedia Patients.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Shiraz University of Medical Sciences · Academic / Other
Sex
All
Age
4 Years – 35 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is determination of the efficacy of combination of hydroxyurea with L-carnitine or magnesium in improving hematologic parameters and cardiac status in patients with β-thalassemia intermedia in comparison with hydroxyurea alone .

Conditions

Interventions

TypeNameDescription
DRUGhydroxyureaHydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
DRUGL-carnitine and hydroxyureaHydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
DRUGhydroxyurea and magnesium chlorideHydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
DRUGhydroxyurea,L-carnitine and magnesium chlorideHydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day

Timeline

Start date
2007-06-01
Primary completion
2007-11-01
Completion
2007-12-01
First posted
2008-12-16
Last updated
2008-12-16

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT00809042. Inclusion in this directory is not an endorsement.